Skip to Content

'
Robert J. Wells, M.D.

Present Title & Affiliation

Primary Appointment

Deputy Division Head, Pediatrics, Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1972 University of California, San Diego, CA, MD, Medicine
1968 Grinnell College, Grinnell, IA, BA, Chemistry

Board Certifications

1982 ABP Subspeciality - Pediatric Hematology/Oncology
1979 American Board of Pediatrics

Experience/Service

Other Appointments/Responsibilities

Member, Family Centered Care Advisory Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008-present

Institutional Committee Activities

Vice Chair, By-Laws Committee, 2008-present
Member, Cancer Survivorship Program Steering Committee, 2006-2010

Selected Publications

Peer-Reviewed Original Research Articles

1. Quezada G, Kopp L, Estey E, Wells RJ. All-trans retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia in a pediatric patient: A case report. Pediatr Blood Cancer 51:133-135, 2008.
2. Meyers PA, Schwartz C, Kailo M, Healey J, Bernstein M, Betcher D, Conrad E, Ferguson WS, Gebhardt M, Goorin A, Harris M, Kleinerman E, Link M, Nadel H, Nieder M, Sato J, Siegel GP, Weiner M, Wells R, Womer R, Grier H. Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival. J Clin Oncol 26:633-638, 2008.

Invited Articles

1. Wells, RJ. Chronic conditions in adult survivors of childhood cancer. Current Oncol Rep 9:435-6, 2007.

Abstracts

1. Noll B, Phipps S, Fernandez LT, Kupst MJ, Weiner L, Sahler OJZ, Maden-Swain A, Vincent N, Mullins LL, Huszti HC, Wells RJ, Robert RS. Current treatment practices of pediatric oncologists management of depression and anxiety disorders in 9 institutions across the United States. Soc Develop Behav Pediatr, 2008.
2. Kumar A, Wells RJ, Soares H, Djulbegovic B. How often do "breakthroughs" interventions discovered in randomized controlled trials conducted during the last 50 years inform current practice. Proc Amer Soc Clin Oncol, 2008.
3. Meyers P, Schwartz C, Kailo M, Kleinerman E, Betcher D, Bernstein M, Conrad E, Ferguson W, Gebhardt M, Goorin A, Harris M, Healy J, Link M, Nadel H, Nieder M, Siegal G, Weiner M, Wells R, Womer R, Grier H. Osteosarcoma: Improved outcome with addition of muramyl tripeptide to cisplatin, doxorubicin, high dose methotrexate +/- ifosfamide. CTOS, 2007.

Letters to the Editor

1. Wells RJ. Complexities in interpretation of osteosarcoma clinical trial results - Reply. J Clin Oncol 26:3104-3105, 2008.

Grant & Contract Support

Title: Physicial Activity to Modify Sequelae and QOL in Childhood ALL: A Nursing Trial
Funding Source: NIH/NCI
Role: Project PI
Principal Investigator: Cox, Cheryl Loraine
Duration: 11/1/2009 - 5/31/2013

Last updated: 8/22/2013